$AMGN Company News Nasdaq breaks out, reaches
Post# of 89388
Posted On: 09/10/2014 10:54:05 AM
$AMGN Company News
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Twitter soars 33% in after hours as results surprise on upside 4:56 p.m. July 29, 2014 - Sue Chang
Zacks Rank #1 Additions for Wednesday - Tale of the Tape 9:30 a.m. Today - Zacks.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Royal Dutch Shell Bond Issue Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More 6:26 p.m. Sept. 8, 2014 - Seeking Alpha
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - CNW Group
3 Stocks Reiterated As A Buy: EBAY, AIG, AMGN 4:48 p.m. Sept. 8, 2014 - TheStreet.com
There Is Further Upside Potential In Regeneron Pharmaceuticals 1:23 p.m. Sept. 8, 2014 - Seeking Alpha
Challenging Consensus On PCSK9 Inhibitors: Focus On Regeneron And Amgen 11:39 a.m. Sept. 8, 2014 - Seeking Alpha
Amgen Is A Great Biotech Stock With A Dividend Kicker 11:22 a.m. Sept. 8, 2014 - Seeking Alpha
Amgen Inc. (AMGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Sept. 8, 2014 - Zacks.com
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label 7:00 a.m. Sept. 8, 2014 - TheStreet.com
College Try: To Offset Tuition, a Bet on Health Care 4:02 p.m. Sept. 7, 2014 - The Wall Street Journal Interactive Edition
Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding 8:27 a.m. Sept. 5, 2014 - benzinga.com
Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab - Analyst Blog 6:00 p.m. Sept. 4, 2014 - Zacks.com
Sanofi Reports Positive Phase III Data on Dengue Vaccine - Analyst Blog 6:40 p.m. Sept. 3, 2014 - Zacks.com
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog 5:20 p.m. Sept. 3, 2014 - Zacks.com
Determining Celgene's Fair Value 11:24 a.m. Sept. 3, 2014 - Seeking Alpha
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog 10:40 a.m. Sept. 3, 2014 - Zacks.com
Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog 10:10 a.m. Sept. 3, 2014 - Zacks.com
United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog 6:25 p.m. Sept. 2, 2014 - Zacks.com
Regeneron/Sanofi Presents Encouraging Alirocumab Data - Analyst Blog 4:30 p.m. Sept. 2, 2014 - Zacks.com
Reporting Bias in Clinical Trials: What's the current status? 23 min ago - PR Newswire - PRF
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9:15 a.m. Today - PR Newswire - PRF
Critical Alerts For Alcoa, Twitter, General Mills, SunEdison and Amgen Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - PR Newswire - PRF
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative 3:13 p.m. Sept. 8, 2014 - BusinessWire - BZX
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals 10:00 a.m. Sept. 8, 2014 - PR Newswire - PRF
Amgen To Present At The Morgan Stanley Global Healthcare Conference 4:04 p.m. Sept. 5, 2014 - PR Newswire - PRF
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck 9:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Cleveland Clinic's 2014 Medical Innovation Summit Examines Cancer Treatment And Personalized Medicine 11:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 8:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate 8:15 a.m. Sept. 4, 2014 - PR Newswire - PRF
Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 8:15 a.m. Sept. 2, 2014 - PR Newswire - PRF
Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency 8:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic 9:30 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol 9:15 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9:00 a.m. Aug. 28, 2014 - PR Newswire - PRF
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 9:15 a.m. Aug. 27, 2014 - PR Newswire - PRF
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 4:55 p.m. Aug. 26, 2014 - PR Newswire - PRF
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell 4:15 p.m. Aug. 25, 2014 - PR Newswire - PRF
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck 9:20 a.m. Aug. 20, 2014 - PR Newswire - PRF
Nasdaq breaks out, reaches less-charted territory 12:05 p.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:56 a.m. Aug. 19, 2014 - Michael Ashbaugh
Nasdaq breaks out, reaches less-charted territory 11:44 a.m. Aug. 19, 2014 - Michael Ashbaugh
Berkshire Hathaway tops $200,000; Cisco drops on results 12:19 p.m. Aug. 14, 2014 - Angela Johnson
Cisco volatile after hours in wake of earnings 5:03 p.m. Aug. 13, 2014 - Sue Chang
Amgen recalls syringes of anemia drug Aranesp 4:55 p.m. Aug. 13, 2014 - Russ Britt
CORRECT: Amgen shares fall after-hours on disappointing trial data 4:34 p.m. Aug. 13, 2014 - Tomi Kilgore
U.S. stocks rally; Dow snaps 4-session losing streak 4:14 p.m. Aug. 4, 2014 - Barbara Kollmeyer
Mobileye rises for second day; Michael Kors falls 1:23 p.m. Aug. 4, 2014 - Angela Johnson
Amgen shares rally 2.7% to top S&P 500 9:30 a.m. Aug. 4, 2014 - Sue Chang
Amgen reports successful late-stage trial of cancer treatment 8:34 a.m. Aug. 4, 2014 - Joshua Jamerson
Amgen reports positive trial of multiple myeloma treatment 7:49 a.m. Aug. 4, 2014 - Ciara Linnane
Tesla Shares Weaken in After Hours 8:13 p.m. July 31, 2014 - MarketWatch
Small health companies see large gains on a big earnings day 5:34 p.m. July 30, 2014 - blogs.marketwatch.com
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 4:26 p.m. July 30, 2014 - MarketWatch
Edwards, Hospira rise as health-care companies see strong earnings 1:08 p.m. July 30, 2014 - blogs.marketwatch.com
Amgen shares hit record on cost-cutting plans 10:50 a.m. July 30, 2014 - blogs.marketwatch.com
Twitter shines; Fed statement and GDP due today 4:38 a.m. July 30, 2014 - MarketWatch
Amgen plans to cut up to 2,900 jobs 9:04 p.m. July 29, 2014 - MarketWatch.com
Twitter soars 33% in after hours as results surprise on upside 4:56 p.m. July 29, 2014 - Sue Chang
Zacks Rank #1 Additions for Wednesday - Tale of the Tape 9:30 a.m. Today - Zacks.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Royal Dutch Shell Bond Issue Leads The 20 Best Value Bond Trades With Maturities Of 1 Year Or More 6:26 p.m. Sept. 8, 2014 - Seeking Alpha
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - CNW Group
3 Stocks Reiterated As A Buy: EBAY, AIG, AMGN 4:48 p.m. Sept. 8, 2014 - TheStreet.com
There Is Further Upside Potential In Regeneron Pharmaceuticals 1:23 p.m. Sept. 8, 2014 - Seeking Alpha
Challenging Consensus On PCSK9 Inhibitors: Focus On Regeneron And Amgen 11:39 a.m. Sept. 8, 2014 - Seeking Alpha
Amgen Is A Great Biotech Stock With A Dividend Kicker 11:22 a.m. Sept. 8, 2014 - Seeking Alpha
Amgen Inc. (AMGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. Sept. 8, 2014 - Zacks.com
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label 7:00 a.m. Sept. 8, 2014 - TheStreet.com
College Try: To Offset Tuition, a Bet on Health Care 4:02 p.m. Sept. 7, 2014 - The Wall Street Journal Interactive Edition
Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding 8:27 a.m. Sept. 5, 2014 - benzinga.com
Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab - Analyst Blog 6:00 p.m. Sept. 4, 2014 - Zacks.com
Sanofi Reports Positive Phase III Data on Dengue Vaccine - Analyst Blog 6:40 p.m. Sept. 3, 2014 - Zacks.com
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog 5:20 p.m. Sept. 3, 2014 - Zacks.com
Determining Celgene's Fair Value 11:24 a.m. Sept. 3, 2014 - Seeking Alpha
Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog 10:40 a.m. Sept. 3, 2014 - Zacks.com
Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog 10:10 a.m. Sept. 3, 2014 - Zacks.com
United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog 6:25 p.m. Sept. 2, 2014 - Zacks.com
Regeneron/Sanofi Presents Encouraging Alirocumab Data - Analyst Blog 4:30 p.m. Sept. 2, 2014 - Zacks.com
Reporting Bias in Clinical Trials: What's the current status? 23 min ago - PR Newswire - PRF
Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 9:15 a.m. Today - PR Newswire - PRF
Critical Alerts For Alcoa, Twitter, General Mills, SunEdison and Amgen Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Zenith Epigenetics Strengthens its Management Team with Key Appointments 5:34 p.m. Sept. 8, 2014 - PR Newswire - PRF
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative 3:13 p.m. Sept. 8, 2014 - BusinessWire - BZX
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals 10:00 a.m. Sept. 8, 2014 - PR Newswire - PRF
Amgen To Present At The Morgan Stanley Global Healthcare Conference 4:04 p.m. Sept. 5, 2014 - PR Newswire - PRF
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck 9:00 a.m. Sept. 5, 2014 - PR Newswire - PRF
Cleveland Clinic's 2014 Medical Innovation Summit Examines Cancer Treatment And Personalized Medicine 11:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 8:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate 8:15 a.m. Sept. 4, 2014 - PR Newswire - PRF
Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 8:15 a.m. Sept. 2, 2014 - PR Newswire - PRF
Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency 8:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic 9:30 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol 9:15 a.m. Aug. 28, 2014 - PR Newswire - PRF
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9:00 a.m. Aug. 28, 2014 - PR Newswire - PRF
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 9:15 a.m. Aug. 27, 2014 - PR Newswire - PRF
Biological Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 4:55 p.m. Aug. 26, 2014 - PR Newswire - PRF
Timothy Leyden Retires As Western Digital CFO, Succeeded By Olivier Leonetti Of Amgen And Formerly At Dell 4:15 p.m. Aug. 25, 2014 - PR Newswire - PRF
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck 9:20 a.m. Aug. 20, 2014 - PR Newswire - PRF
(0)
(0)